0001567619-21-001669.txt : 20210128
0001567619-21-001669.hdr.sgml : 20210128
20210128165926
ACCESSION NUMBER: 0001567619-21-001669
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210126
FILED AS OF DATE: 20210128
DATE AS OF CHANGE: 20210128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lackner Mark
CENTRAL INDEX KEY: 0001777413
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38915
FILM NUMBER: 21566054
MAIL ADDRESS:
STREET 1: C/O IDEAYA BIOSCIENCES, INC.
STREET 2: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc.
CENTRAL INDEX KEY: 0001676725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474268251
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-6209
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Ideaya Biosciences, Inc.
DATE OF NAME CHANGE: 20160609
4
1
doc1.xml
FORM 4
X0306
4
2021-01-26
0
0001676725
IDEAYA Biosciences, Inc.
IDYA
0001777413
Lackner Mark
C/O IDEAYA BIOSCIENCES, INC.
7000 SHORELINE COURT, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
SVP, Head of Biology
Common Stock
2021-01-26
4
M
0
377
4.62
A
1378
D
Common Stock
2021-01-26
4
M
0
1123
6.98
A
2501
D
Common Stock
2021-01-26
4
S
0
1701
18.2977
D
800
D
Common Stock
2021-01-26
4
S
0
800
18.7919
D
0
D
Stock Option (right to buy)
4.62
2021-01-26
4
M
0
377
0.00
D
2028-06-20
Common Stock
377
61760
D
Stock Option (right to buy)
6.98
2021-01-26
4
M
0
1123
0.00
D
2028-12-11
Common Stock
1123
35014
D
Includes 1,001 shares acquired pursuant to Issuer's Employee Stock Purchase Plan on November 30, 2020.
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades in prices ranging from $17.68 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $18.68 to $18.895, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
25% of the shares subject to the option vest on the first anniversary measured from May 31, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
/s/ Jason Throne, as Attorney-in-Fact for Mark Lackner
2021-01-28